Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pyxis Oncology (PYXS) Gains from Investment Securities: 2024-2025

Historic Gains from Investment Securities for Pyxis Oncology (PYXS) over the last 1 years, with Jun 2025 value amounting to $12.7 million.

  • Pyxis Oncology's Gains from Investment Securities rose 32508.73% to $12.7 million in Q2 2025 from the same period last year, while for Jun 2025 it was $12.7 million, marking a year-over-year change of. This contributed to the annual value of $9.7 million for FY2024, which is 2082.26% up from last year.
  • According to the latest figures from Q2 2025, Pyxis Oncology's Gains from Investment Securities is $12.7 million, which was up 4.00% from $12.2 million recorded in Q1 2025.
  • Pyxis Oncology's 5-year Gains from Investment Securities high stood at $12.7 million for Q2 2025, and its period low was $39,000 during Q2 2024.
  • For the 2-year period, Pyxis Oncology's Gains from Investment Securities averaged around $7.8 million, with its median value being $7.0 million (2024).
  • Data for Pyxis Oncology's Gains from Investment Securities shows a peak YoY soared of 32,508.73% (in 2025) over the last 5 years.
  • Quarterly analysis of 2 years shows Pyxis Oncology's Gains from Investment Securities stood at $7.0 million in 2024, then skyrocketed by 32,508.73% to $12.7 million in 2025.
  • Its Gains from Investment Securities stands at $12.7 million for Q2 2025, versus $12.2 million for Q1 2025 and $7.0 million for Q3 2024.